Assembly Biosciences, Inc. (ASMB)

In the past six months, Assembly Biosciences reported Q4 2025 earnings with positive results, followed by a Q1 2026 loss that missed estimates. The company has a consensus rating of "Moderate Buy" from Wall Street analysts. The company highlighted presentations on positive Phase 1b data for its HSV candidates, ABI-5366 and ABI-1179, at the ESCMID Global 2026 conference. In August 2025, the company completed a $175 million equity raise. ASMB stock has seen a 1.52% increase over the past six months.

As a clinical-stage biotechnology company without approved commercial products, Assembly Biosciences, Inc. does not experience direct demand seasonality. The company's revenue is primarily derived from collaboration agreements and research and development activities, which are not subject to seasonal fluctuations in consumer demand.

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for serious viral diseases. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals industries. Its pipeline includes therapies targeting Herpes Simplex Virus (HSV), Hepatitis D Virus (HDV), Hepatitis B Virus (HBV), and transplant-associated herpesviruses. The company generates revenue through strategic partnerships and R&D services, including a collaboration with Gilead Sciences, Inc.

Assembly Biosciences, Inc. is headquartered in South San Francisco, California, United States. The company has a global presence through its subsidiaries, which include Assembly Pharmaceuticals, Inc. (Delaware), Assembly Biosciences Ireland Limited (Ireland), ASMB Microbiome China Holdco Limited (Ireland), ASMB HBV China Holdco Limited (Ireland), Assembly Biotechnology Development (Shanghai) Co, Ltd. (China), Assembly Biosciences Hong Kong Limited (Hong Kong), and Assembly Biosciences Cayman (Cayman Islands).

Assembly Biosciences' brand reputation has been shaped by its scientific advancements and strategic corporate activities. Positive Phase 1b data for its HSV candidates at scientific conferences has bolstered its scientific credibility. The collaboration with Gilead Sciences, Inc. provides non-dilutive funding and validates Assembly Bio's platform. The discontinuation of vebicorvir and workforce reduction streamlined the pipeline, providing financial stability. The company has a consensus "Moderate Buy" rating from analysts.

Assembly Biosciences, Inc. has a concentrated ownership structure. Gilead Sciences, Inc. is the largest single shareholder, holding 29.0% of the company's shares. Major institutional owners include Farallon Capital Management Llc, Ra Capital Management, L.p., and Commodore Capital Lp, among others. Individual investors hold 5.1% of the shares, and company insiders hold 5.3% of the remaining float.